AI drug discovery · BioHive supercomputer
Recursion Pharmaceuticals
An AI drug-discovery firm. It trains foundation models on 23PB of proprietary bio/chem data and runs the NVIDIA-GPU BioHive-2 supercomputer (NVIDIA invested $50M in 2023, trimmed the stake in Feb 2026 while the collaboration continues). Partners with Roche, Genentech and Sanofi. Q4 2025 revenue $35.5M (incl. a $30M Roche milestone). An AI demand node that buys compute to make drugs.
Business categories AI Drug Discovery & Precision Medicine · Biopharma & Life Sciences · primary Enterprise & Industry AI Applications · Cloud & Enterprise Software
RXRX Updated Jul 12, 2026 7 AI consumers· 5 recurring
Per the valuechain.wiki graph, Recursion Pharmaceuticals is directly linked to 2 companies (2 supply, 0 revenue, 1 investment relationships) and reaches 54 companies within two hops; the links are backed by 5 dated sources, 1 of them primary filings (as of 2026-07-12).
Financials & Segments
- Total revenue · Q4 2025 revenue $35.5M
- Customer concentration · 23PB data, BioHive-2 (NVIDIA); Roche milestone.
- Segments · Collaboration (Roche, Sanofi) · Own pipeline · OS/data
Revenue from
- Roche · Sanofi · pharma (collaboration · milestones) High confidence· Amount $30M · 로슈 마일스톤 · Roche collaboration milestone
Collaboration with Roche, Genentech and Sanofi, with milestones (Roche $30M).Confirms EN Yahoo Finance Published Feb 26, 2026: Recursion details Sanofi/Roche milestones, runway to 2028 - In-house drug pipeline (clinical) Medium confidence
Clinical progress of its own AI-discovered pipeline.Confirms EN Kavout Published Jan 1, 2026: Recursion, an AI drug-discovery powerhouse (23PB, BioHive-2)
Pays to
- NVIDIA High confidence· Amount $50M · 2023 전략투자 · NVIDIA strategic investment (stake unwound 2026.2)
Builds and runs the BioHive-2 supercomputer on NVIDIA GPUs (foundation-model training). - Alphabet (Google) High confidence
Runs Recursion OS and its data platform on Google Cloud (primary cloud since 2019: GKE, Compute Engine, BigQuery, storage); 2024 expansion adds Gemini. Separate infrastructure layer from the in-house BioHive-2 GPUs.Confirms EN PR Newswire Published Oct 21, 2024: Recursion and Google Cloud announce expansion of partnershipConfirms EN Google Cloud Published Mar 1, 2019: Recursion Pharmaceuticals accelerates drug discovery with Google Cloud - Cloud · experiments · wet lab (undisclosed) Low confidence
Cloud, automated wet-lab and data generation.Confirms EN Kavout Published Jan 1, 2026: Recursion, an AI drug-discovery powerhouse (23PB, BioHive-2)
Investors
- NVIDIA Medium confidence
NVIDIA made a $50M strategic investment in 2023 (stake trimmed Feb 2026, collaboration continues).Confirms EN Yahoo Finance Published Feb 26, 2026: Recursion details Sanofi/Roche milestones, runway to 2028
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals | node | · | -55 | +27.9 | -31.4 | -39.5 | +6.6 |
| NVIDIA | benef1 | +125.5 | -50.3 | +239 | +171.2 | +38.9 | +23.2 |
| Alphabet (Google) | benef1 | +65.3 | -39.1 | +58.3 | +36 | +66 | +8.3 |
| Nan Ya PCB | benef2 | +110.6 | -46.7 | -0.5 | -38.3 | +188.2 | +280.5 |
| Micron Technology | benef2 | +24.2 | -45.9 | +71.9 | -1 | +240.2 | +256.4 |
| Unimicron | benef2 | +133.5 | -30.2 | +35.2 | -19.7 | +175.7 | +236.2 |
| ASE Technology | benef2 | +38.3 | -12.8 | +60.9 | +10.1 | +65.6 | +191.3 |
| Nebius Group | benef2 | · | · | · | · | +202.2 | +170.5 |
| Marvell | benef2 | +84.6 | -57.5 | +63.7 | +83.8 | -22.8 | +163.4 |
| Intel | benef2 | +6.1 | -46.6 | +94.6 | -59.6 | +84 | +159.6 |
| Kioxia | benef2 | · | · | · | · | +1082.1 | +155 |
| Ibiden | benef2 | +30.4 | -19.6 | +51.6 | -38.6 | +261 | +149.3 |
| Lumentum | benef2 | +11.6 | -50.7 | +0.5 | +60.1 | +339.1 | +139.1 |
| Murata Manufacturing | benef2 | -14 | -11.7 | +24.7 | -16.5 | +29.9 | +131.5 |
| Astera Labs | benef2 | · | · | · | · | +25.6 | +105.7 |
| Wiwynn | benef2 | +24.7 | -22.3 | +206.4 | +3.5 | +64.4 | +92.3 |
| SK hynix | benef2 | -0.4 | -25.6 | +53.9 | +48.6 | +361.1 | +85.3 |
| Flex Ltd. | benef2 | +1.9 | +17.1 | +41.9 | +67.2 | +57.4 | +81.2 |
| Corning | benef2 | +5.9 | -11.6 | -1.2 | +60.6 | +87.8 | +77.2 |
| Coherent | benef2 | -10 | -48.6 | +24 | +117.6 | +94.8 | +69.4 |
| Samsung Electronics | benef2 | -9 | -14.2 | +20.9 | -26.4 | +212.9 | +63.8 |
| Delta Electronics | benef2 | -3.4 | +10.4 | -0.3 | +59.2 | +183.8 | +61.9 |
| Keysight Technologies | benef2 | +56.3 | -17.2 | -7 | +1 | +26.5 | +61 |
| GE Vernova | benef2 | · | · | · | · | +99 | +54 |
| Monolithic Power | benef2 | +35.5 | -27.8 | +79.8 | -5.6 | +54.5 | +53.7 |
| Analog Devices | benef2 | +21 | -4.9 | +23.4 | +8.8 | +29.8 | +51.1 |
| TSMC | benef2 | +12.1 | -36.7 | +42.3 | +92.6 | +55.9 | +50.3 |
| Wistron | benef2 | +7.9 | +9.7 | +272.7 | -1.6 | +22.7 | +49.7 |
| Arista Networks | benef2 | +97.9 | -15.6 | +94.1 | +87.7 | +18.5 | +47.9 |
| TeraWulf | benef2 | +77.1 | -95.5 | +258.2 | +135.8 | +103 | +43.7 |
| Alchip Technologies | benef2 | +14.3 | -8.7 | +365.1 | -18.9 | +0.8 | +40.1 |
| onsemi | benef2 | +107.5 | -8.2 | +33.9 | -24.5 | -14.1 | +37.4 |
| Eaton | benef2 | +46.7 | -7.2 | +56.2 | +39.5 | -2.8 | +36 |
| Pegatron | benef2 | -5.9 | +0.6 | +35.3 | +21.2 | -23.8 | +34.5 |
| Amphenol | benef2 | +34.9 | -12 | +31.5 | +41.3 | +96.1 | +29.8 |
| Eoptolink | benef2 | -10.1 | -27.7 | +136.6 | +197 | +368.8 | +29.1 |
| InnoLight | benef2 | -30.7 | -18.3 | +253.7 | +12 | +468.1 | +25.6 |
| Digital Realty | benef2 | +30.7 | -41 | +39.9 | +35.9 | -10.1 | +23.4 |
| Quanta Computer | benef2 | +22.2 | -12.8 | +254.5 | +12.7 | +8.9 | +21.2 |
| ABB | benef2 | +23.9 | +7.3 | +18.9 | +39 | +36.1 | +18.4 |
| Foxconn (Hon Hai) | benef2 | -5.1 | +2.8 | +7.8 | +80.1 | +26.9 | +16.3 |
| Schneider Electric | benef2 | +25.9 | +1.6 | +25.8 | +36.1 | +0.5 | +11.7 |
| King Yuan Electronics (KYEC) | benef2 | +26.7 | -7.7 | +132.4 | +38.6 | +171 | +8.4 |
| NextEra Energy | benef2 | +23.4 | -8.5 | -25.3 | +21.5 | +15.5 | +6.2 |
| Duke Energy Corporation | benef2 | +19.1 | +2 | -1.6 | +15.6 | +12.7 | +5.3 |
| Ameren Corporation | benef2 | +17.1 | +2.5 | -16.1 | +27.5 | +15.3 | +4.5 |
| Xcel Energy | benef2 | +4.4 | +6.4 | -8.7 | +12.3 | +13.9 | +4.1 |
| BlackRock | benef2 | +29.4 | -20.4 | +17.9 | +29.3 | +6.6 | +2.8 |
| Berkshire Hathaway | benef2 | +29 | +3.3 | +15.5 | +27.1 | +10.9 | +0.7 |
| TE Connectivity | benef2 | +35.1 | -27.7 | +24.6 | +3.5 | +61.1 | -3 |
| Luxshare Precision | benef2 | -11.9 | -30.2 | -21.2 | +58.8 | +29.3 | -7.4 |
| Comcast Corporation | benef2 | -2.2 | -28.7 | +29.1 | -11.8 | -17.3 | -22.3 |
| BYD Electronics | benef2 | -56.1 | +16 | -0.4 | +60.6 | -19.4 | -24.1 |
YTD as of 2026-10-09 · source: Yahoo Finance
Recursion Pharmaceuticals operates across NASDAQ, AI drug discovery, BioHive supercomputer. It remained weak at -39.5% in 2025 and -11.2% in 2026. The supply side (avg +16%) leads the stock (-11.2%), with spending rippling down to suppliers first. Among connected nodes the furthest ahead is NVIDIA (+23.7%) and the furthest behind is Alphabet (Google) (+8.3%). If chain logic explains the gap, the laggard is the next propagation candidate; if not, the link itself deserves a second look. An AI demand node that buys compute to make drugs.
Analysis generated from returns as of 2026-09-04Analyst ratings
Consensus: Buy 1 · Hold 2 · Sell 0 · Avg. target $7 · Price $4.36 (10-09) · Upside +61%
Analyses covering this node
- Orders are measured, revenue is narrative: on every frontier, infrastructure re-rates first Jun 23, 2026
- The application is still a story, the infrastructure demand is already measured: techbio as the first case Jun 23, 2026
← All companiesMarkdown · JSON · Customers · Suppliers · Ripple · Consensus